CLDN18 and neoplasm: Cohort C is evaluating osemitamab plus CAPOX as first-line therapy for CLDN18.2-positive (IHC ≥ 1+ in ≥10% of tumor cells), HER2-negative or unknown, advanced/metastatic GAC/GEJ [34,35].